56.71 USD
↗ 1.43 (2.59%)AT CLOSE (11:59 AM EDT)
Travere Therapeutics, Inc. Common Stock
TVTXNASDAQ • USD
56.00
↘ 0.71 (1.25%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
56.00
↘ 0.71 (1.25%)
Market: CLOSED
Travere Therapeutics, Inc. Common Stock (TVTX) trades at $56.68 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, TVTX trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Jul 17, 2026.
Open?$54.12
High?$57.30
Low?$53.00
Prev. Close?$55.28
Volume?1.5M
Avg. Volume?2.1M
VWAP?$56.52
Rel. Volume?0.72x
Bid / Ask
Bid?$49.20 × 100
Ask?$67.26 × 100
Spread?$18.06
Midpoint?$58.23
Valuation & Ratios
Market Cap?5.1B
Shares Out?93.0M
Float?90.4M
Float %?98.0%
P/E Ratio?N/A
P/B Ratio?52.07
EPS?-$0.23
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Themes
Address
3611 VALLEY CENTRE DR
SAN DIEGO, CA 92130
Phone: 888-969-7879
SAN DIEGO, CA 92130
Phone: 888-969-7879
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?93
Momentum?57
Short Sent.?65
Piotroski F-Score?4/9Mixed
Altman Z-Score?4.15Safe
Confidence?65%Moderate
Short InterestHigh
Short % of Float?14.04%High
Short Interest?12.7M
Days to Cover?4.7
Free Float90.4M
Avg Daily Volume2.7M
Settlement Date2026-06-30
Financial Health
Current Ratio?3.13Strong
Quick Ratio?3.08Strong
Cash Ratio?0.62Adequate
Debt/Equity?3.16High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score33/100
P/E?N/A▾
P/B?52.07HIGH▾
Peers100
S&P3
P/S?9.59HIGH▾
Peers100
S&P9
P/FCF?131.0PRICEY▾
Peers100
S&P3
EV/EBITDA?334.0HIGH▾
Peers100
S&P3
EV/Sales?10.02HIGH▾
Peers100
S&P11
Returns & Efficiency
ROE?-21.7%WEAK▾
S&P7
ROA?-3.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$39.2M
Enterprise Value?$5.4B
Fundamentals ratios updated end of day